Dr Gerard Kaiko
Senior Lecturer
School of Biomedical Sciences and Pharmacy
- Email:gerard.kaiko@newcastle.edu.au
- Phone:(02) 40420184
Career Summary
Biography
Dr Kaiko UON Senior Lecturer, and Theme Leader for Stem Cells and Organoids in Mucosal Diseases (HMRI IHP Program), and previously an NHMRC CJ Martin and Career Development Fellow.
Background
Dr Kaiko's PhD studies in respiratory disease and immunology examined the role of the innate immune system in regulating the interaction between viral infections and asthma. After a stint working in London at NIMR (MRC), Dr Kaiko moved to Washington University in St Louis, USA in 2013. There he transitioned to the study of adult stem cells, as well as the study of the microbiota in gastrointestinal diseases. In these fields he has published in some of the world's top tier journals including Cell 2016, Science 2017, and Science Translational Medicine 2019. His work in microbial metabolomics and intestinal disease has been the feature of media articles in multiple news outlets. While working in the USA, Dr Kaiko was part of a team that developed a novel 3D technology to generate epithelial stem cells from all regions of the gastrointestinal and respiratory systems. These stem cells or "organoids" are cultured in vitro and retain their properties of the mammalian host long term. Only a tiny patient biopsy is required to grow these stem cells in the laboratory. They can then be expanded and re-differentiated into mature "organ-like" tissues to conduct an unlimited array of 3D or 2D tests, including drug discovery, diagnostic tests for personalised medicine, toxicology screening, and better understanding of disease mechanisms.
Current Focus and Projects:
Dr Kaiko's research group studies:
1) Mucosal organoids (in particular those generated from the lung and gastrointestinal tract) as tools for drug discovery in inflammatory bowel diseases, cystic fibrosis, asthma and lung cancer.
2) The role of mucosal stem cells in tissue regeneration in the lung and gastrointestinal tract, and their interaction with stromal and immune cells in health and disease.
3) Mining the gut microbiome for drug discovery
4) Developing organoid screening assays for translational medicine. As the healthcare system evolves and more and more therapeutic options become available for mucosal diseases, this stem cell technology will also be used to improve precision medicine through personalised organoid assays that can match the right patient to the most optimal therapy in real-time. This work is now the subject of a national clinical trial enabling precision medicine in cystic fibrosis.
5) Developing humanised organoid assays for environmental toxicological analysis.
Qualifications
- PhD (Immunology & Microbiology), University of Newcastle
Keywords
- Adult stem cells
- Asthma
- Colorectal cancer
- Cystic Fibrosis
- Inflammatory Bowel Disease
- Mucosal Immunology
- Regenerative medicine
- Tissue repair
Fields of Research
Code | Description | Percentage |
---|---|---|
320606 | Regenerative medicine (incl. stem cells) | 30 |
320103 | Respiratory diseases | 35 |
320209 | Gastroenterology and hepatology | 35 |
Professional Experience
UON Appointment
Title | Organisation / Department |
---|---|
Senior Lecturer | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Academic appointment
Dates | Title | Organisation / Department |
---|---|---|
1/2/2015 - 1/1/2018 | Research Associate | Washington University In St. Louis Pathology and Immunology United States |
10/1/2013 - 31/1/2015 | NHMRC CJ Martin (Overseas) fellow | Washington University In St. Louis Pathology and Immunology United States |
1/1/2012 - 3/12/2012 | Postdoctoral researcher | National Institute of Medical Research (MRC), Mill Hill, London United Kingdom |
Teaching
Code | Course | Role | Duration |
---|---|---|---|
HUBS1422 |
Critical Scientific Thinking Skills College of Health, Medicine & Wellbeing - The University of Newcastle |
Lecturer | 1/3/2022 - 1/1/0001 |
HUBS2206 |
Human Biochemistry and Cell Biology College Health, Medicine and Wellbeing - The University of Newcastle (Australia) |
Lecturer | 1/3/2022 - 1/1/0001 |
MED2101 |
Medicine - Genetics College of Health, Medicine and Wellbeing, University of Newcastle |
Lecturer | 1/7/2022 - 1/1/0001 |
HUBS3602 |
Clinical Immunology and Infection Faculty of Health, University of Newcastle |
Lecturer | 1/2/2021 - 1/1/0001 |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Chapter (1 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2019 |
Bruce J, Kaiko GE, Keely S, 'Isolation and in vitro culture of human gut progenitor cells', Methods in Molecular Biology, Humana, New York, NY 49-62 (2019) [B1]
|
Nova |
Journal article (41 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2023 |
Sikder MAA, Rashid RB, Ahmed T, Sebina I, Howard DR, Ullah MA, et al., 'Maternal diet modulates the infant microbiome and intestinal Flt3L necessary for dendritic cell development and immunity to respiratory infection.', Immunity, 56 1098-1114.e10 (2023) [C1]
|
Nova | |||||||||
2023 |
Bernstein IR, Nixon B, Lyons JM, Damyanova KB, De Oliveira CS, Mabotuwana NS, et al., 'The hypoxia-inducible factor EPAS1 is required for spermatogonial stem cell function in regenerative conditions', iScience, 26 108424-108424 (2023) [C1]
|
Nova | |||||||||
2023 |
Gilbert B, Kaiko G, Smith S, Wark P, 'A systematic review of the colorectal microbiome in adult cystic fibrosis patients.', Colorectal Dis, 25 843-852 (2023) [C1]
|
Nova | |||||||||
2022 |
Jamaluddin MFB, Ghosh A, Ingle A, Mohammed R, Ali A, Bahrami M, et al., 'Bovine and human endometrium-derived hydrogels support organoid culture from healthy and cancerous tissues', Proceedings of the National Academy of Sciences, 119 (2022) [C1]
|
Nova | |||||||||
2022 |
Dowling LR, Strazzari MR, Keely S, Kaiko GE, 'Enteric nervous system and intestinal epithelial regulation of the gut-brain axis', Journal of Allergy and Clinical Immunology, 150 513-522 (2022) [C1] The gut-brain axis describes a bidirectional interplay within the enteric environment between the intestinal epithelium, the mucosal immune system, and the microbiota with the ent... [more] The gut-brain axis describes a bidirectional interplay within the enteric environment between the intestinal epithelium, the mucosal immune system, and the microbiota with the enteric nervous system. This interplay provides a link between exogenous environmental stimuli such as nutrient sensing, and nervous system function, as well as a mechanism of feedback from cortical and sensory centers of the brain to enteric activities. The intestinal epithelium is one of the human body's largest sources of hormones and neurotransmitters, which have critical effects on neuronal function. The influence of the gut microbiota on these processes appears to be profound; yet to date, it has been insufficiently explored. Disruption of the intestinal microbiota is linked not only to diseases in the gut but also to brain symptomatology, including neurodegenerative and behavioral disorders (Parkinson disease, Alzheimer disease, autism, and anxiety and/or depression). In this review we discuss the cellular wiring of the gut-brain axis, with a particular focus on the epithelial and neuronal interaction, the evidence that has led to our current understanding of the intestinal role in neurologic function, and future directions of research to unravel this important interaction in both health and allergic disease.
|
Nova | |||||||||
2022 |
Bruce JK, Burns GL, Sinn Soh W, Nair PM, Sherwin S, Fan KN, et al., 'Defects in NLRP6, autophagy and goblet cell homeostasis are associated with reduced duodenal CRH receptor 2 expression in patients with functional dyspepsia', Brain, Behavior, and Immunity, 101 335-345 (2022) [C1] Functional dyspepsia (FD) affects up to 15% of the population and is characterised by recurring upper gastrointestinal (GI) symptoms occurring in the absence of clinically identif... [more] Functional dyspepsia (FD) affects up to 15% of the population and is characterised by recurring upper gastrointestinal (GI) symptoms occurring in the absence of clinically identifiable pathology. Psychological stress is a key factor associated with the onset of FD and locally acting hypothalamic¿pituitary¿adrenal (HPA) axis hormones have been implicated in GI motility and barrier dysfunction. Recent pre-clinical work has identified mechanistic pathways linking corticotropin-releasing hormone (CRH) with the innate epithelial immune protein NLRP6, an inflammasome that has been shown to regulate GI mucus secretion. We recruited twelve FD patients and twelve healthy individuals to examine whether dysregulation of hypothalamic-pituitary adrenal (HPA) axis hormones and altered NLRP6 pathways were evident in the duodenal mucosa. Protein expression was assessed by immunoblot and immunohistochemistry in D2 duodenal biopsies. Plasma HPA axis hormones were assayed by ELISA and enteroid and colorectal cancer cell line cultures were used to verify function. FD patients exhibited reduced duodenal CRH-receptor 2, compared to non-GI disease controls, indicating a dysregulation of duodenal HPA signalling. The loss of CRH-receptor 2 correlated with reduced NLRP6 expression and autophagy function, processes critical for maintaining goblet cell homeostasis. In accordance, duodenal goblet cell numbers and mucin exocytosis was reduced in FD patients compared to controls. In vitro studies demonstrated that CRH could reduce NLRP6 in duodenal spheroids and promote mucus secretion in the HT29-MTX-E12 cell line. In conclusion, FD patients exhibit defects in the NLRP6-autophagy axis with decreased goblet cell function that may drive symptoms of disease. These features correlated with loss of CRH receptor 2 and may be driven by dysregulation of HPA signalling in the duodenum of FD patients.
|
Nova | |||||||||
2021 |
Bekkers M, Stojkovic B, Kaiko GE, 'Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22 (2021) [C1]
|
Nova | |||||||||
2021 |
Wark PAB, Pathinayake PS, Kaiko G, Nichol K, Ali A, Chen L, et al., 'ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma', Respirology, 26 442-451 (2021) [C1] Background and objective: COVID-19 is complicated by acute lung injury, and death in some individuals. It is caused by SARS-CoV-2 that requires the ACE2 receptor and serine protea... [more] Background and objective: COVID-19 is complicated by acute lung injury, and death in some individuals. It is caused by SARS-CoV-2 that requires the ACE2 receptor and serine proteases to enter AEC. We determined what factors are associated with ACE2 expression particularly in patients with asthma and COPD. Methods: We obtained lower AEC from 145 people from two independent cohorts, aged 2¿89 years, Newcastle (n = 115) and Perth (n = 30), Australia. The Newcastle cohort was enriched with people with asthma (n = 37) and COPD (n = 38). Gene expression for ACE2 and other genes potentially associated with SARS-CoV-2 cell entry was assessed by qPCR, and protein expression was confirmed with immunohistochemistry on endobronchial biopsies and cultured AEC. Results: Increased gene expression of ACE2 was associated with older age (P = 0.03) and male sex (P = 0.03), but not with pack-years smoked. When we compared gene expression between adults with asthma, COPD and healthy controls, mean ACE2 expression was lower in asthma patients (P = 0.01). Gene expression of furin, a protease that facilitates viral endocytosis, was also lower in patients with asthma (P = 0.02), while ADAM-17, a disintegrin that cleaves ACE2 from the surface, was increased (P = 0.02). ACE2 protein expression was also reduced in endobronchial biopsies from asthma patients. Conclusion: Increased ACE2 expression occurs in older people and males. Asthma patients have reduced expression. Altered ACE2 expression in the lower airway may be an important factor in virus tropism and may in part explain susceptibility factors and why asthma patients are not over-represented in those with COVID-19 complications.
|
Nova | |||||||||
2021 |
Barnes JL, Plank MW, Asquith K, Maltby S, Sabino LR, Kaiko GE, et al., 'T-helper 22 cells develop as a distinct lineage from Th17 cells during bacterial infection and phenotypic stability is regulated by T-bet', MUCOSAL IMMUNOLOGY, 14 1077-1087 (2021) [C1]
|
Nova | |||||||||
2020 |
Sokulsky LA, Garcia-Netto K, Nguyen TH, Girkin JLN, Collison A, Mattes J, et al., 'A critical role for the CXCL3/CXCL5/CXCR2 neutrophilic chemotactic axis in the regulation of type 2 responses in a model of rhinoviral-induced asthma exacerbation', Journal of Immunology, 205 2468-2478 (2020) [C1]
|
Nova | |||||||||
2020 |
Sokulsky LA, Goggins B, Sherwin S, Eyers F, Kaiko GE, Board PG, et al., 'GSTO1-1 is an upstream suppressor of M2 macrophage skewing and HIF-1a-induced eosinophilic airway inflammation', CLINICAL AND EXPERIMENTAL ALLERGY, 50 609-624 (2020) [C1]
|
Nova | |||||||||
2020 |
Ali A, Tan H, Kaiko GE, 'Role of the Intestinal Epithelium and Its Interaction With the Microbiota in Food Allergy', FRONTIERS IN IMMUNOLOGY, 11 (2020) [C1]
|
Nova | |||||||||
2019 |
Starkey MR, Plank MW, Casolari P, Papi A, Pavlidis S, Guo Y, et al., 'IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis', EUROPEAN RESPIRATORY JOURNAL, 54 (2019) [C1]
|
Nova | |||||||||
2019 |
Kaiko GE, Chen F, Lai C-W, Chiang I-L, Perrigoue J, Stojmirovic A, et al., 'PAI-1 augments mucosal damage in colitis', SCIENCE TRANSLATIONAL MEDICINE, 11 (2019) [C1]
|
Nova | |||||||||
2018 |
Liu TC, Kern JT, VanDussen KL, Xiong S, Kaiko GE, Wilen CB, et al., 'Interaction between smoking and ATG16L1 It is suggested that subtyping of complex inflammatory diseases can be based on genetic susceptibility and relevant environmental exposure (G+E). We propose that using matched cel... [more] It is suggested that subtyping of complex inflammatory diseases can be based on genetic susceptibility and relevant environmental exposure (G+E). We propose that using matched cellular phenotypes in human subjects and corresponding preclinical models with the same G+E combinations is useful to this end. As an example, defective Paneth cells can subtype Crohn's disease (CD) subjects; Paneth cell defects have been linked to multiple CD susceptibility genes and are associated with poor outcome. We hypothesized that CD susceptibility genes interact with cigarette smoking, a major CD environmental risk factor, to trigger Paneth cell defects. We found that both CD subjects and mice with ATG16L1T300A (T300A; a prevalent CD susceptibility allele) developed Paneth cell defects triggered by tobacco smoke. Transcriptional analysis of full-thickness ileum and Paneth cell-enriched crypt base cells showed the T300A-smoking combination altered distinct pathways, including proapoptosis, metabolic dysregulation, and selective downregulation of the PPAR¿ pathway. Pharmacologic intervention by either apoptosis inhibitor or PPAR¿ agonist rosiglitazone prevented smoking-induced crypt apoptosis and Paneth cell defects in T300A mice and mice with conditional Paneth cell-specific knockout of Atg16l1. This study demonstrates how explicit G+E can drive disease-relevant phenotype and provides rational strategies for identifying actionable targets.
|
||||||||||
2018 |
Ryu SH, Kaiko GE, Stappenbeck TS, 'Cellular differentiation: Potential insight into butyrate paradox?', Molecular and Cellular Oncology, 5 (2018) [C1] We recently demonstrated that cellular responses to butyrate depend on the differentiation status of the colonic epithelium. Here, we apply the implications of these findings to c... [more] We recently demonstrated that cellular responses to butyrate depend on the differentiation status of the colonic epithelium. Here, we apply the implications of these findings to cancer biology and discuss discrepancies in the effects of butyrate on cancer progression.
|
||||||||||
2017 |
Steed AL, Christophi GP, Kaiko GE, Sun L, Goodwin VM, Jain U, et al., 'The microbial metabolite desaminotyrosine protects from influenza through type I interferon', Science, 357 498-502 (2017) [C1] The microbiota is known to modulate the host response to influenza infection through as-yet-unclear mechanisms. We hypothesized that components of the microbiota exert effects thr... [more] The microbiota is known to modulate the host response to influenza infection through as-yet-unclear mechanisms. We hypothesized that components of the microbiota exert effects through type I interferon (IFN), a hypothesis supported by analysis of influenza in a gain-of-function genetic mouse model. Here we show that a microbially associated metabolite, desaminotyrosine (DAT), protects from influenza through augmentation of type I IFN signaling and diminution of lung immunopathology. A specific human-associated gut microbe, Clostridium orbiscindens, produced DAT and rescued antibiotic-treated influenza-infected mice. DAT protected the host by priming the amplification loop of type I IFN signaling. These findings show that specific components of the enteric microbiota have distal effects on responses to lethal infections through modulation of type I IFN.
|
||||||||||
2017 |
Plank MW, Kaiko GE, Maltby S, Weaver J, Tay HL, Shen W, et al., 'Th22 Cells Form a Distinct Th Lineage from Th17 Cells In Vitro with Unique Transcriptional Properties and Tbet-Dependent Th1 Plasticity.', JOURNAL OF IMMUNOLOGY, 198 2182-2190 (2017) [C1]
|
Nova | |||||||||
2017 |
Foster PS, Maltby S, Rosenberg HF, Tay HL, Hogan SP, Collison AM, et al., 'Modeling T
|
Nova | |||||||||
2016 |
Kaiko GE, Ryu SH, Koues OI, Collins PL, Solnica-Krezel L, Pearce EJ, et al., 'The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites', Cell, 165 1708-1720 (2016) [C1] In the mammalian intestine, crypts of Leiberkühn house intestinal epithelial stem/progenitor cells at their base. The mammalian intestine also harbors a diverse array of microbial... [more] In the mammalian intestine, crypts of Leiberkühn house intestinal epithelial stem/progenitor cells at their base. The mammalian intestine also harbors a diverse array of microbial metabolite compounds that potentially modulate stem/progenitor cell activity. Unbiased screening identified butyrate, a prominent bacterial metabolite, as a potent inhibitor of intestinal stem/progenitor proliferation at physiologic concentrations. During homeostasis, differentiated colonocytes metabolized butyrate likely preventing it from reaching proliferating epithelial stem/progenitor cells within the crypt. Exposure of stem/progenitor cells in vivo to butyrate through either mucosal injury or application to a naturally crypt-less host organism led to inhibition of proliferation and delayed wound repair. The mechanism of butyrate action depended on the transcription factor Foxo3. Our findings indicate that mammalian crypt architecture protects stem/progenitor cell proliferation in part through a metabolic barrier formed by differentiated colonocytes that consume butyrate and stimulate future studies on the interplay of host anatomy and microbiome metabolism.
|
||||||||||
2015 |
Hickey CA, Kuhn KA, Donermeyer DL, Porter NT, Jin C, Cameron EA, et al., 'Colitogenic Bacteroides thetaiotaomicron antigens access host immune cells in a sulfatase-dependent manner via outer membrane vesicles', Cell Host and Microbe, 17 672-680 (2015) [C1] Microbes interact with the host immune system via several potential mechanisms. One essential step for each mechanism is the method by which intestinal microbes or their antigens ... [more] Microbes interact with the host immune system via several potential mechanisms. One essential step for each mechanism is the method by which intestinal microbes or their antigens access specific host immune cells. Using genetically susceptible mice (dnKO) that develop spontaneous, fulminant colitis, triggered by Bacteroides thetaiotaomicron (B. theta), we investigated the mechanism of intestinal microbial access under conditions that stimulate colonic inflammation. B. theta antigens localized to host immune cells through outer membrane vesicles (OMVs) that harbor bacterial sulfatase activity. We deleted the anaerobic sulfatase maturating enzyme (anSME) from B. theta, which is required for post-translational activation of all B. theta sulfatase enzymes. This bacterial mutant strain did not stimulate colitis in dnKO mice. Lastly, access of B. theta OMVs to host immune cells was sulfatase dependent. These data demonstrate that bacterial OMVs and associated enzymes promote inflammatory immune stimulation in genetically susceptible hosts.
|
||||||||||
2015 |
Tay HL, Kaiko GE, Plank M, Li J, Maltby S, Essilfie A-T, et al., 'Correction: Antagonism of miR-328 Increases the Antimicrobial Function of Macrophages and Neutrophils and Rapid Clearance of Non-typeable Haemophilus Influenzae (NTHi) from Infected Lung.', PLoS pathogens, 11 e1004956 (2015) [O1]
|
||||||||||
2015 |
Tay HL, Kaiko GE, Plank M, Li JJ, Maltby S, Essilfie AT, et al., 'Antagonism of miR-328 Increases the Antimicrobial Function of Macrophages and Neutrophils and Rapid Clearance of Non-typeable Haemophilus Influenzae (NTHi) from Infected Lung', PLoS Pathogens, 11 (2015) [C1] Pathogenic bacterial infections of the lung are life threatening and underpin chronic lung diseases. Current treatments are often ineffective potentially due to increasing antibio... [more] Pathogenic bacterial infections of the lung are life threatening and underpin chronic lung diseases. Current treatments are often ineffective potentially due to increasing antibiotic resistance and impairment of innate immunity by disease processes and steroid therapy. Manipulation miRNA directly regulating anti-microbial machinery of the innate immune system may boost host defence responses. Here we demonstrate that miR-328 is a key element of the host response to pulmonary infection with non-typeable haemophilus influenzae and pharmacological inhibition in mouse and human macrophages augments phagocytosis, the production of reactive oxygen species, and microbicidal activity. Moreover, inhibition of miR-328 in respiratory models of infection, steroid-induced immunosuppression, and smoke-induced emphysema enhances bacterial clearance. Thus, miRNA pathways can be targeted in the lung to enhance host defence against a clinically relevant microbial infection and offer a potential new anti-microbial approach for the treatment of respiratory diseases.
|
Nova | |||||||||
2014 |
Kaiko GE, Stappenbeck TS, 'Host-microbe interactions shaping the gastrointestinal environment', Trends in Immunology, 35 538-548 (2014) Tremendous advances have been made in mapping the complexity of the human gut microbiota in both health and disease states. These analyses have revealed that, rather than a conste... [more] Tremendous advances have been made in mapping the complexity of the human gut microbiota in both health and disease states. These analyses have revealed that, rather than a constellation of individual species, a healthy microbiota comprises an interdependent network of microbes. The microbial and host interactions that shape both this network and the gastrointestinal environment are areas of intense investigation. Here we review emerg-ing concepts of how microbial metabolic processes con-trol commensal composition, invading pathogens, immune activation, and intestinal barrier function. We posit that all of these factors are critical for the mainte-nance of homeostasis and avoidance of overt inflamma- tory disease. A greater understanding of the underlying mechanisms will shed light on the pathogenesis of many diseases and guide new therapeutic interventions.
|
||||||||||
2013 | Kaiko G, Loh Z, Spann K, Lynch J, Lalwani A, Davidson S, et al., 'TLR7 gene deficiency and early-life pneumovirus infection interact to predispose toward the development of asthma-like pathology in mice', EUROPEAN RESPIRATORY JOURNAL, 42 (2013) | ||||||||||
2013 |
Kaiko GE, Loh Z, Spann K, Lynch JP, Lalwani A, Zheng Z, et al., 'Toll-like receptor 7 gene deficiency and early-life
|
Nova | |||||||||
2013 |
Foster PS, Plank MW, Collison AM, Tay HL, Kaiko GE, Li J, et al., 'The emerging role of microRNAs in regulating immune and inflammatory responses in the lung', Immunological Reviews, 253 198-215 (2013) [C1]
|
Nova | |||||||||
2013 |
Hansbro PM, Scott GV, Essilfie A-T, Kim RY, Starkey MR, Nguyen D, et al., 'Th2 cytokine antagonists: Potential treatments for severe asthma', Expert Opinion on Investigational Drugs, 22 49-69 (2013) [C1]
|
Nova | |||||||||
2011 |
Kaiko GE, Foster PS, 'New insights into the generation of Th2 immunity and potential therapeutic targets for the treatment of asthma', Current Opinion in Allergy and Clinical Immunology, 11 39-45 (2011) [C1]
|
Nova | |||||||||
2011 |
Asquith KL, Horvat JC, Kaiko GE, Carey AJ, Beagley KW, Hansbro PM, Foster PS, 'Interleukin-13 promotes susceptibility to chlamydial infection of the respiratory and genital tracts', PLoS Pathogens, 7 (2011) [C1]
|
Nova | |||||||||
2011 |
Hansbro PM, Kaiko GE, Foster PS, 'Cytokine/anti-cytokine therapy - Novel treatments for asthma?', British Journal of Pharmacology, 163 81-95 (2011) [C2]
|
Nova | |||||||||
2011 |
Davidson SK, Kaiko GE, Loh Z, Lalwani A, Zhang V, Spann K, et al., 'Plasmacytoid Dendritic Cells promote host defense against Acute Pneumovirus infection via the TLR7-MyD88-Dependent signaling pathway', Journal of Immunology, 186 5938-5948 (2011) [C1]
|
Nova | |||||||||
2010 |
Kaiko GE, Phipps S, Angkasekwinai P, Dong C, Foster PS, 'NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25', Journal of Immunology, 185 4681-4690 (2010) [C1]
|
Nova | |||||||||
2009 |
Phipps S, Lam CE, Kaiko GE, Foo A, Collison AM, Mattes J, et al., 'Toll/IL-1 signaling is critical for house dust mite-specific Th1 and Th2 responses', American Journal of Respiratory and Critical Care Medicine, 179 883-893 (2009) [C1]
|
Nova | |||||||||
2008 |
Kaiko GE, Horvat JC, Beagley KW, Hansbro PM, 'Immunological decision-making: How does the immune system decide to mount a helper T-cell response?', Immunology, 123 326-338 (2008) [C1]
|
Nova | |||||||||
2008 |
Kaiko GE, Phipps S, Hickey DK, Lam CE, Hansbro PM, Foster PS, Beagley KW, 'Chlamydia muridarum infection subverts dendritic cell function to promote Th2 immunity and airways hyperreactivity', Journal of Immunology, 180 2225-2232 (2008) [C1]
|
Nova | |||||||||
2007 |
Horvat JC, Beagley KW, Wade MA, Preston JA, Hansbro NG, Hickey DK, et al., 'Neonatal chlamydial infection induces mixed T-cell responses that drive allergic airway disease', American Journal of Respiratory and Critical Care Medicine, 176 556-564 (2007) [C1]
|
Nova | |||||||||
Show 38 more journal articles |
Conference (19 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2020 |
Wark P, Pathinyake P, Kaiko G, Sohal S, Oldmeadow C, Bartlett N, et al., 'Late Breaking Abstract-ACE2 expression in lower airway epithelial cells is increased with age and in males, but is less in asthma', EUROPEAN RESPIRATORY JOURNAL (2020)
|
|||||||
2017 |
Plank M, Kaiko G, Maltby S, Weaver J, Tay H, Wei S, et al., 'Th22 cells develop independently of the Th17 lineage with unique transcriptional properties and plasticity toward Th1-type cells during Influenza infection', EUROPEAN RESPIRATORY JOURNAL, Milan, ITALY (2017)
|
|||||||
2017 |
Plank MW, Kaiko GE, Maltby S, Weaver J, Tay H, Shen W, et al., 'TH22 CELLS FORM A DISTINCT TH LINEAGE FROM TH17 CELLS
|
|||||||
2015 |
Plank M, Kaiko G, Maltby S, Tay H, Stewart J, Durum S, Foster P, 'Mapping the cellular source and role of IL-22 in murine lung infections', EUROPEAN RESPIRATORY JOURNAL (2015)
|
|||||||
2015 |
Tay H, Kaiko G, Plank M, Li J, Essilfie A, Maltby S, et al., 'THE ROLE OF MIR-328 IN RESPIRATORY DISEASES', RESPIROLOGY, Queensland, AUSTRALIA (2015) [E3]
|
|||||||
2015 |
Tay H, Kaiko G, Mattes J, Hansbro P, Foster P, 'The role of miR-328 in respiratory diseases', JOURNAL OF IMMUNOLOGY, New Orleans, LA (2015)
|
|||||||
2013 | Tay H, Kaiko G, Hansbro P, Foster P, 'The role of miRNA in regulating bacterial clearance', JOURNAL OF IMMUNOLOGY, Honolulu, HI (2013) [E3] | |||||||
2012 | Kaiko GE, Tay HL, Plank MW, Hansbro PM, Foster PS, 'MicroRNA regulate bacterial phagocytosis in the lung', Immunology: Abstracts of the European Congress of Immunology, Glasgow, Scotland (2012) [E3] | |||||||
2012 | Kaiko GE, Phipps S, Plank MW, Tay HL, Lam CE, Foster PS, 'Inhibition of microRNA reverses CD8 T cell exhaustion and improves immunity against respiratory virus infection', Respirology, Canberra, ACT (2012) [E3] | |||||||
2012 |
Plank MW, Kaiko GE, Luck H, Li J, Mattes J, Hansbro PM, Foster PS, 'The role of micrornas in CD4 T cell function', Respirology, Canberra, ACT (2012) [E3]
|
|||||||
2012 |
Tay HL, Kaiko GE, Plank MW, Mattes J, Hansbro PM, Foster PS, 'MiRNAs regulate bacterial infection in lungs', Respirology, Canberra, ACT (2012) [E3]
|
|||||||
2011 |
Foster PS, Tay HL, Kaiko GE, Plank MW, Mattes J, Hansbro PM, 'MiRNA and its roles in regulating bacterial infection in lungs', American Journal of Respiratory and Critical Care Medicine, Denver, CO (2011) [E3]
|
|||||||
2007 | Phipps S, Lam CE, Kaiko GE, Collison A, Smith L, Mansell A, et al., 'Contribution of multiple toll-like receptors to the development of murine allergic airways inflammation', Immunology and Cell Biology, Manly, NSW (2007) [E3] | |||||||
2007 | Kaiko GE, Phipps S, Foster PS, 'Importance of CD4 T cells in the clearance of a primary Respiratory Syncytial Virus infection and in protection against the development of exhausted CD8 T cell memory', Immunology and Cell Biology, Manly, NSW (2007) [E3] | |||||||
2007 | Kaiko GE, Phipps S, Foster PS, 'Respiratory Syncytial Virus up-regulates PD-1 expression; comparison to a model of CD8 T cell exhaustion in BALB/c mice', Immuno 2007: 13th International Congress of Immunology, Abstracts and Posters, Rio de Janeiro, Brazil (2007) [E3] | |||||||
2006 | Kaiko GE, Phipps S, Lam CE, Hickey DK, Hansbro NG, Foster PS, Beagley KW, 'The chlamydia infection of dendritic cells drives the development of a pro-asthmatic response', Immunology and Cell Biology, Auckland, NZ (2006) [E3] | |||||||
2005 |
Horvat JC, Wade MA, Preston JA, Newcombe N, Ferguson AL, Kaiko G, et al., 'Neonatal But Not Adult Chlamydial Infection Induces the Development of Allergic Airways Disease Through Novel Mechanisms Involving Inflammation of Mixed Phenotype', Tissue Antigens, Melbourne, Australia (2005) [E3]
|
|||||||
Show 16 more conferences |
Preprint (1 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2020 |
Wark PAB, Pathinayake P, Kaiko G, Nichol K, Ali A, Chen L, et al., 'ACE2 Expression is elevated in Airway Epithelial Cells from aged and male donors but reduced in asthma (2020)
|
Grants and Funding
Summary
Number of grants | 24 |
---|---|
Total funding | $7,917,219 |
Click on a grant title below to expand the full details for that specific grant.
20241 grants / $50,000
Newcastle Human Organoid Program for Effective New Therapies (New HOPE – New Therapies) $50,000
Funding body: Jessie Speight Bequest
Funding body | Jessie Speight Bequest |
---|---|
Project Team | Professor Jay Horvat, Professor Chris Dayas, Conjoint Associate Professor Christopher Grainge, Doctor Gerard Kaiko, Professor Simon Keely |
Scheme | Research Funding |
Role | Investigator |
Funding Start | 2024 |
Funding Finish | 2024 |
GNo | G2400300 |
Type Of Funding | Scheme excluded from IGS |
Category | EXCL |
UON | Y |
20235 grants / $1,243,274
Combining multi-omic causal-prediction networks from large patient datasets with a human intestinal organoid pipeline to identify new therapies for IBD$984,565
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Gerard Kaiko, Doctor Ayesha Ayesha, Associate Professor Lauren Peters, Lauren Peters |
Scheme | Ideas Grants |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2026 |
GNo | G2200449 |
Type Of Funding | C1100 - Aust Competitive - NHMRC |
Category | 1100 |
UON | Y |
A new treatment for inflammatory bowel diseases (IBD) Crohn's disease and ulcerative colitis$93,765
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Gerard Kaiko |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2024 |
GNo | G2201272 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
A cellular system for the manufacture of exosome-based targeted RNA therapies$80,000
Funding body: NSW Ministry of Health
Funding body | NSW Ministry of Health |
---|---|
Project Team | Doctor Gerard Kaiko |
Scheme | RNA Future Leaders PhD Program |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2026 |
GNo | G2200074 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
Identifying molecular pathways for severe CF liver disease and predicting risk of CFTR modulators-induced liver injury using iPSC-derived hepatic organoids$79,977
Funding body: Australian Cystic Fibrosis Research Trust
Funding body | Australian Cystic Fibrosis Research Trust |
---|---|
Project Team | Doctor Nikhil Awatade, Doctor Kurtis Budden, Doctor Gerard Kaiko, Conjoint Professor Peter Wark |
Scheme | CFWA Golf Classic Innovation Grant |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2300491 |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | Y |
Plasma bio-engineered hydrogel bandages$4,967
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Doctor Behnam Akhavan, Doctor Gerard Kaiko |
Scheme | Pilot Funding Scheme |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2300486 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20223 grants / $2,778,743
A precision medicine clinical trial platform to BEAT CF$2,185,693
Funding body: Department of Health and Aged Care
Funding body | Department of Health and Aged Care |
---|---|
Project Team | Conjoint Professor Peter Wark, Professor Adam Jaffe, Doctor Gerard Kaiko, Prof James McGree, AProf Andre Schultz, Prof Thomas Snelling, Dr Shafagh Waters |
Scheme | Clinical Trials Activity - Rare Cancers, Rare Diseases and Unmet Need |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2024 |
GNo | G2100963 |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | Y |
Exosome delivered CFTR activator to improve CFTR function in cystic fibrosis$498,050
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Gerard Kaiko, Conjoint Professor Peter Wark |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2023 |
GNo | G2201181 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Stem Cell Research - Cystic Fibrosis$95,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Gerard Kaiko, Doctor Gabriela Araujo Hoefel, Dr LING Chen, Professor Paul Foster, Conjoint Professor Peter Wark |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | G2200313 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20213 grants / $206,250
Testing KB407 in patient-derived CFTR models$141,250
Funding body: Krystal Australia Pty Ltd
Funding body | Krystal Australia Pty Ltd |
---|---|
Project Team | Doctor Gerard Kaiko, Conjoint Professor Peter Wark |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2100511 |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | Y |
Development of translational prognostic tool to identify T cell responses in COVID 19 patients$55,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Conjoint Professor Peter Wark, Professor Paul Foster, Doctor Hock Tay, Doctor Gerard Kaiko, A/Prof Brian Oliver, A/Prof Ben Kwan, Dr Carlos Riveros |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2100232 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
MRFF Support Grant: accelerated silicosis$10,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Jay Horvat, Doctor Dusan Ilic, Professor Carole James, Conjoint Professor Peter Wark, Professor Paul Foster, Doctor Gerard Kaiko, Doctor Hock Tay, Prof Darryl Knight, A/Prof Brian Oliver, Dr Cecilia Prele |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2001499 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20203 grants / $1,808,307
Using advanced technologies to investigate the impact of PFAS exposure on the human mucosal barrier and interaction with pre-existing medical conditions$944,382
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Gerard Kaiko, Professor Paul Foster, Professor Paul Foster, Professor Ravi Naidu, Professor Ravi Naidu, Doctor Heather Lee, Doctor Heather Lee |
Scheme | Targeted Call for Research - Per and Poly-Fluoroalkylated Substances (PFAS) |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2024 |
GNo | G1900620 |
Type Of Funding | C1100 - Aust Competitive - NHMRC |
Category | 1100 |
UON | Y |
High resolution biomarker identification by scRNA-seq to predict response to Mab (Choosebetweenamab)$471,525
Funding body: GlaxoSmithKline (GSK) Research & Development Limited
Funding body | GlaxoSmithKline (GSK) Research & Development Limited |
---|---|
Project Team | Doctor Gerard Kaiko, Conjoint Professor Peter Wark |
Scheme | Research Award |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2022 |
GNo | G2000389 |
Type Of Funding | C3400 – International For Profit |
Category | 3400 |
UON | Y |
Synthetic Biology: from Genomics to Valuable Bioproducts$392,400
Funding body: ARC (Australian Research Council)
Funding body | ARC (Australian Research Council) |
---|---|
Project Team | Professor Brett Neilan, Associate Professor Karl Hassan, Associate Professor Karl Hassan, Doctor Emma Beckett, Doctor Emma Beckett, Aaron Darling, Doctor Gerard Kaiko, Doctor Gerard Kaiko, Professor Marc Wilkins, Professor Marc Wilkins, Belinda Ferrari, Belinda Ferrari, Lawrence Lee, Lawrence Lee, Professor Ian Paulsen, Professor Ian Paulsen, Dr Amy Cain, Dr Amy Cain, Aaron Darling |
Scheme | Linkage Infrastructure Equipment & Facilities (LIEF) |
Role | Investigator |
Funding Start | 2020 |
Funding Finish | 2022 |
GNo | G1900156 |
Type Of Funding | Scheme excluded from IGS |
Category | EXCL |
UON | Y |
20193 grants / $582,223
Investigation of the role of novel cell types and metabolites in the pathogenesis of asthma$452,652
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Gerard Kaiko |
Scheme | Career Development Fellowships |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2022 |
GNo | G1800379 |
Type Of Funding | C1100 - Aust Competitive - NHMRC |
Category | 1100 |
UON | Y |
Optimising patient-derived stem cell technology in cystic fibrosis to predict drug responsiveness$80,000
Funding body: Thoracic Society of Australia and New Zealand
Funding body | Thoracic Society of Australia and New Zealand |
---|---|
Project Team | Doctor Gerard Kaiko, Conjoint Professor Peter Wark, Shafagh Water, Dr Shafagh Waters, Professor Adam Jaffe |
Scheme | TSANZ / Australian Cystic Fibrosis Research Trust Innovation Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2020 |
GNo | G1900147 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Developing a personalised clinical test in cystic fibrosis: Patient-derived stem cell technology to predict CFTR drug responsiveness$49,571
Funding body: Ramaciotti Foundations
Funding body | Ramaciotti Foundations |
---|---|
Project Team | Doctor Gerard Kaiko |
Scheme | Health Investment Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1900500 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
20182 grants / $873,778
Functional characterisation of novel metabolites in asthma and identification of new biomarkers $847,778
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Gerard Kaiko, Professor Paul Foster |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2021 |
GNo | G1700376 |
Type Of Funding | C1100 - Aust Competitive - NHMRC |
Category | 1100 |
UON | Y |
Mini-organs in a dish: a personalised test for cystic fibrosis treatment to reduce the need for lung transplantation$26,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Gerard Kaiko, Dr LING Chen, Conjoint Professor Peter Wark |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2019 |
GNo | G1801337 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20171 grants / $20,000
Precision medicine in Cystic Fibrosis: A personalised test to target individual mutations to specific CFTR modulators$20,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Gerard Kaiko, Conjoint Professor Peter Wark |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | G1701536 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20132 grants / $349,964
Investigating the interaction between susceptibility genes, viral infection, and gut microbiota in inflammation and epithelial repair processes$329,964
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Gerard Kaiko |
Scheme | Early Career Fellowships |
Role | Lead |
Funding Start | 2013 |
Funding Finish | 2018 |
GNo | G1100647 |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | Y |
DP73 Digital colour and monochrome camera + cellSens software + Xcite120 fluorescence lamp illuminator$20,000
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Professor Paul Foster, Doctor Alan Hsu, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Katie Baines, Professor Jodie Simpson, Professor Rakesh Kumar, Doctor Nicole Hansbro, Doctor Steven Maltby, Associate Professor Ming Yang, Doctor Gerard Kaiko, Professor Jay Horvat, Professor Simon Keely, Doctor Andrew Jarnicki, Doctor Michael Fricker |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2013 |
Funding Finish | 2013 |
GNo | G1201186 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
1 grants / $4,680
Service contract for IncuCyte ZOOM live-cell imaging system$4,680
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kelly Kiejda, Doctor Brianna Morten, Doctor Gerard Kaiko |
Scheme | Early and Mid-Career Equipment Grant |
Role | Investigator |
Funding Start | |
Funding Finish | |
GNo | G1900064 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Research Supervision
Number of supervisions
Current Supervision
Commenced | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2024 | PhD | Plasma Bio-Engineering of Nano-Hybrid Scaffolds for Bone Tissue Engineering | PhD (Medical Engineering), College of Engineering, Science and Environment, The University of Newcastle | Co-Supervisor |
2024 | PhD | Identification of IBD-Related Microbial Biomarkers: Towards Targeted Therapies for Inflammatory Bowel Disease | PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2023 | Masters | ORganoId GuIded N-of-1 (ORIGIN-1) trial | M Philosophy (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2023 | PhD | Understanding the Mechanism of Exacerbation of Asthma | PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2023 | PhD | Development of a Regenerative Intestinal Stem Cell Technology with a Functionalised Nanomaterial Surgical Mesh for Enhanced Healing of Intestinal Surgical Anastomoses. | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2023 | PhD | Hydrogel-Solid Degradable Surgical Meshes for Tissue Engineering and Regenerative Medicine | PhD (Medical Engineering), College of Engineering, Science and Environment, The University of Newcastle | Co-Supervisor |
2023 | PhD | Treating Monogenic Diseases (Cystic Fibrosis, Polycystic Kidney Diseases) Using Patients' Organoids As A Disease Model And RNA Therapies As The Treatment. | PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2021 | Masters | Colorectal Cancer in Cystic Fibrosis: An Australian Perspective | M Philosophy (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2020 | PhD | Investigation of Epithelial Key Disease-driver Genes (KDGs) in Inflammatory Bowel Disease | PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2020 | PhD | Gut Microbiome Metatranscriptomics for Identifying Novel Drug Targets in Inflammatory Bowel Disease | PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2019 | Honours | Microbial metabolite ROS screen | Pharmacy, University of Newcastle | Principal Supervisor |
Past Supervision
Year | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2023 | PhD | Characterisation of CD4+ T-helper 22 Lymphocytes During Bacterial Infection of the Mucosa | PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2017 | PhD | Wound-associated epithelial genes in Inflammatory Bowel Disease | Pathology, Washington University In St. Louis | Principal Supervisor |
News
News • 17 Nov 2023
Making IBS medicine with artificial intelligence
Artificial Intelligence (AI) is supporting researchers with important exploration into new therapies for Inflammatory Bowel Disease (IBD) and ulcerative colitis, made possible by a $98,700 grant from Newcastle Permanent Charitable Foundation.
News • 15 Dec 2022
Spinal cord pain to PTSD: $5.2m in NHMRC grants to target pressing medical conditions
Both the body and the mind will be a key focus for innovative researchers from the University of Newcastle, who were successful in the latest round of National Health and Medical Research Council (NHMRC) Ideas Grants.
News • 18 Dec 2019
NHMRC awards $9.3 million to 13 University of Newcastle projects
The University of Newcastle has received more than $9.3 million in funding to support projects aiming to solve some of the world’s most critical health problems and improve the lives of millions of Australians.
News • 16 Aug 2018
Funding success to address chronic disease
Researchers from the University of Newcastle have received more than $5.8 million in funding from the National Health and Medical Research Council (NHMRC), in addition to the $1.4 million for male and female health strategies announced earlier this week.
Dr Gerard Kaiko
Position
Senior Lecturer
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing
Contact Details
gerard.kaiko@newcastle.edu.au | |
Phone | (02) 40420184 |
Office
Building | HMRI |
---|---|
Location | Level 2 East Hunter Medical Research Institute (HMRI) , |